CMS Revisiting Coverage Policies for Aprepitant and AmyvidDecember 18th 2012
The specialty pharmacy community should remain alert in the coming months as the MEDCAC receives public comments and considers the future of Medicare coverage for 2 major therapies. The MEDCAC decision can have far-reaching impact on patient access.
Impact of CMS' Proposed Sunshine Reporting RuleApril 9th 2012
Compliance with the much-anticipated implementation of the "Sunshine Act" will impact specialty pharmacies nationwide. Our experts take a closer look at the potential changes and how they will affect the industry now and in the future.